MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)*
Organization & Developments: Madrigal
Parents
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)*
Children
*Clinical-stage biopharmaceutical company developing treatments for cardiovascular, metabolic, and liver diseases.
2017: Madrigal Pharmaceuticals: Buy The Secondary - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
2018: Madrigal Pharmaceuticals: Buy The Dip - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
2018: Madrigal price target raised to $156 from $105 at H.C. Wainwright MDGL
2018: NASH Series 5 - Diagnosis: The Challenge And A Look At Madrigal_eekingalpha.com
2019: Madrigal: A Basic Overview _seekingalpha.com
2019: Madrigal: Beyond NASH_seekingalpha.com
2020: Madrigal: Beyond NASH_seekingalpha.com
2021: Madrigal Pharmaceuticals: Leading The NASH Innovation
2021: Madrigal: Leading Biotech In Race For NASH Approval That Nobody Has Been Able To Win
2022: Madrigal Pharmaceuticals Breaks Through In NASH With Late-Stage Win
2022: Madrigal Pharmaceuticals Forecast: Not So Clear_ seekingalpha.com
2022: Madrigal Pharmaceuticals: The Wait For Pivotal NASH Data Must End Soon_ seekingalpha.com
2022: Madrigal: Binary Catalyst Unlocking_ seekingalpha.com
2022: Madrigal: End Of 2022 NASH Data For Multi-Billion Dollar Market_seekingalpha.com
2023: Madrigal Pharmaceuticals Bolstered By $500 Million Equity Infusion Is A 'Buy' Into 2024_seekingalpha.com
2023: Madrigal Pharmaceuticals: Preparing For Resmetirom's Commercialization In 2024 (MDGL)
2024: FDA approves first MASH drug: Madrigal's Rezdiffra breaks ground in notorious biopharma graveyard
2024: Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play_ seekingalpha.com
2024: Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown
2024: Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
2024: Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
2024: Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead
2024: NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal
2024: Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets
2024: Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion_seekingalpha.com
2024: StockWatch: Madrigal Shares Soar as FDA Nears Historic MASH Decision
2024: While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
2025: In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals
2025: Madrigal gets EU nod for its MASH treatment
2025: Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
2025: Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MAS
2025: Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
2025: Madrigal Pharmaceuticals: GLP-1s Inch Closer To MASH Market As REZDIFFRA Outperforms
2025: Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)
Jumps
*Key People: Madrigal
Finance & Acquisition: Madrigal